Denmark’s medical cannabis pilot program notched one other positive quarter, however the variety of distinctive customers stays effectively beneath the trial’s peak of a 12 months in the past.
The Danish market’s struggles display how companies must issue market ebbs and flows into their projections reasonably than relying on constant, perpetual progress.
In the second quarter of 2020, the variety of distinctive sufferers receiving a prescription for merchandise included within the nation’s pilot scheme was 408, greater than the 341 reported within the earlier quarter, based on information just lately disclosed by the nation’s official e-health portal.
Doctors wrote 1,038 prescriptions for merchandise included within the scheme within the April-June interval, up from the 825 issued in the course of the first quarter of the 12 months.
Since the start of 2020, solely 4 merchandise have been out there in Denmark below the experiment. Those embrace:
- Three styles of Bedrocan flower imported by Danish distributor Canngros from the Netherlands.
- THC capsules imported into Denmark by Alberta, Canada-based Aurora Cannabis.
During the second quarter of 2020, 135 packages of Aurora capsules – every containing 100 models – had been offered to sufferers.
About 10 kilograms of flower (22 kilos) – 1 kilogram greater than the earlier quarter – had been offered within the April-June interval.
The income generated at a retail stage by flower gross sales was a bit of greater than $255,000, whereas gross sales of Aurora’s capsules had been price virtually $32,000.
The pilot program began in January 2018 and loved speedy progress till mid-2019, when about 1,000 sufferers had been receiving 1,800 prescriptions per quarter.
The variety of sufferers sharply declined within the second half of 2019.
The experiment has had 2,550 sufferers thus far.
At least 4 out of 5 sufferers within the pilot program have been older than 40 to this point. Three out of 5 have been ladies.
About half the prescriptions had been written to deal with neuropathic ache.
Accounting for all medical cannabis merchandise, together with these offered exterior the trial program, whole gross sales in the course of the second quarter had been about $2 million.
The majority was generated from magistral preparations with pure THC or pure CBD – no full-spectrum merchandise – and, to a lesser extent, completed pharmaceutical medicines comparable to Sativex.
Considering all varieties of merchandise, 5,800 sufferers obtained a prescription for medical cannabis at the very least as soon as from January 2018 till June 2020 – most for remoted cannabinoids magistral preparations.
Alfredo Pascual might be reached at [email protected]